Quantitative modeling of the physiology of ascites in portal hypertension

BMC Gastroenterology

Michael D Levitt¹  David G Levitt² 

[1]Research Service, Veterans Affairs Medical Center, VAMC/111D, 1 Veterans Drive, Minneapolis, MN 55417, USA

[2]Department of Integrative Biology and Physiology, University of Minnesota, 6-125 Jackson Hall, 321 Church St. S. E., Minneapolis, MN 55455, USA

关键词: Wedge pressure;    Portal hypertension;    Cirrhosis;    Ascites;   

Others  :  1113120
DOI  :  10.1186/1471-230X-12-26

 received in 2011-12-15, accepted in 2012-03-27,  发布年份 2012

【 摘 要 】

Although the factors involved in cirrhotic ascites have been studied for a century, a number of observations are not understood, including the action of diuretics in the treatment of ascites and the ability of the plasma-ascitic albumin gradient to diagnose portal hypertension. This communication presents an explanation of ascites based solely on pathophysiological alterations within the peritoneal cavity. A quantitative model is described based on experimental vascular and intraperitoneal pressures, lymph flow, and peritoneal space compliance. The model's predictions accurately mimic clinical observations in ascites, including the magnitude and time course of changes observed following paracentesis or diuretic therapy.

【 授权许可】

   
2012 Levitt and Levitt; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Starling EH: On the absorption of fluids from the connective tissue spaces. J Physiol 1896, 19(4):312-326.
• [2]Rocco VK, Ware AJ: Cirrhotic ascites. Pathophysiology, diagnosis, and management. Ann Intern Med 1986, 105(4):573-585.
• [3]Dudley FJ: Pathophysiology of ascites formation. Gastroenterol Clin N Am 1992, 21(1):215-235.
• [4]Epstein M (Ed): The Kidney in Liver Disease. thirdth edition. Baltimore: Williams & Wilkins; 1988.
• [5]Wong F, Girgrah N, Blendis L: Review: the controversy over the pathophysiology of ascites formation in cirrhosis. J Gastroenterol Hepatol 1997, 12(6):437-444.
• [6]Moller S, Henriksen JH, Bendtsen F: Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009, 44(8):902-911.
• [7]Rosner MH, Gupta R, Ellison D, Okusa MD: Management of cirrhotic ascites: physiological basis of diuretic action. Eur J Intern Med 2006, 17(1):8-19.
• [8]La Villa G, Gentilini P: Hemodynamic alterations in liver cirrhosis. Mol Aspects Med 2008, 29(1-2):112-118.
• [9]Cardenas A, Bataller R, Arroyo V: Mechanisms of ascites formation. Clin Liver Dis 2000, 4(2):447-465.
• [10]Kashani A, Landaverde C, Medici V, Rossaro L: Fluid retention in cirrhosis: pathophysiology and management. QJM 2008, 101(2):71-85.
• [11]Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, et al.: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38(1):258-266.
• [12]Takasaki S, Hano H: Three-dimensional observations of the human hepatic artery (Arterial system in the liver). J Hepatol 2001, 34(3):455-466.
• [13]Witte CL, Witte MH, Dumont AE, Frist J, Cole WR: Lymph protein in hepatic cirrhosis and experimental hepatic and portal venous hypertension. Ann Surg 1968, 168(4):567-577.
• [14]Cobb WS, Burns JM, Kercher KW, Matthews BD, James Norton H, Todd Heniford B: Normal intraabdominal pressure in healthy adults. J Surg Res 2005, 129(2):231-235.
• [15]Johnson PC, Richardson DR: The influence of venous pressure on filtration forces in the intestine. Microvasc Res 1974, 7(3):296-306.
• [16]Cogger VC, Le Couteur DG: Fenestrations in the liver sinusoidal endothelial cell. In The Liver: Biology and Pathobiology. 5th edition. Edited by Aria IM. Chichester: John Wiley & Sons, Ltd; 2009.
• [17]Laine GA, Hall JT, Laine SH, Granger J: Transsinusoidal fluid dynamics in canine liver during venous hypertension. Circ Res 1979, 45(3):317-323.
• [18]Barrowman JA, Granger DN: Effects of experimental cirrhosis on splanchnic microvascular fluid and solute exchange in the rat. Gastroenterology 1984, 87(1):165-172.
• [19]Abu-Hijleh MF, Habbal OA, Moqattash ST: The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 1995, 186(Pt 3):453-467.
• [20]Mactier RA, Khanna R, Twardowski Z, Moore H, Nolph KD: Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 1987, 80(5):1311-1316.
• [21]Schilling JA, Mc CA, Clausen SW, Troup SB, Mc KF: Experimental ascites; studies of electrolyte balance in dogs with partial and complete occlusion of the portal vein and of the vena cava above and below the liver. J Clin Invest 1952, 31(7):702-710.
• [22]Webster GJ, Burroughs AK, Riordan SM: Review article: portal vein thrombosis--new insights into aetiology and management. Aliment Pharmacol Ther 2005, 21(1):1-9.
• [23]Davis MJ, Gore RW: Capillary pressures in rat intestinal muscle and mucosal villi during venous pressure elevation. Am J Physiol 1985, 249(1 Pt 2):H174-H187.
• [24]Witte CL, Myers JF, Witte MH, Katz MA: Transcapillary water and protein flux in the canine intestine with acute and chronic extrahepatic portal hypertension. Circ Res 1983, 53(5):622-629.
• [25]Bolton C, Barnard WG: The pathological occurences in the liver in experimental venous stagnation. J Pathol Bacteriol 1931, 34(6):701-709.
• [26]Greenway CV, Lautt WW: Effects of hepatic venous pressure on transsinusoidal fluid transfer in the liver of the anesthetized cat. Circ Res 1970, 26(6):697-703.
• [27]Hyatt RE, Lawrence GH, Smith JR: Observations on the origin of ascites from experimental hepatic congestion. J Lab Clin Med 1955, 45(2):274-280.
• [28]Dumont AE, Mulholland JH: Alterations in thoracic duct lymph flow in hepatic cirrhosis: significance in portal hypertension. Ann Surg 1962, 156(4):668-675.
• [29]Kuntz E, Kuntz H: Hepatology textbook and atlas: history, morphology, biochemisty, diagnostics, clinic, therapy. 3rd edition. Heidelberg: Springer; 2008.
• [30]Tameda Y, Yoshizawa N, Takase K, Nakano T, Kosaka Y: Prognostic value of peritoneoscopic findings in cirrhosis of the liver. Gastrointest Endosc 1990, 36(1):34-38.
• [31]Heit HA, Johnson LF, Rabin L: Liver surface characteristics as observed during laparoscopy correlated with biopsy findings. Gastrointest Endosc 1978, 24(6):288-290.
• [32]Braet F, Wisse E: Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002, 1(1):1. BioMed Central Full Text
• [33]Henriksen JH, Horn T, Christoffersen P: The blood-lymph barrier in the liver. A review based on morphological and functional concepts of normal and cirrhotic liver. Liver 1984, 4(4):221-232.
• [34]Dudley FJ: Management of refractory ascites. J Gastroenterol Hepatol 2004, 19:S194-S199.
• [35]Khalid SK, Garcia-Tsao G: Ascites. Clinical features, diagnosis and natural history. In Portal Hypertension. Edited by Sanyal AJ, Shah VH. Totowa: Humana Press, Inc; 2005:285-299.
• [36]Guyton AC: Textbook of medical Physiology. 6th edition. W. B. Saunders: Philadelphia; 1981.
• [37]Witte MH, Witte CL, Dumont AE: Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology 1971, 61(5):742-750.
• [38]Shibayama Y, Nakata K: Localization of increased hepatic vascular resistance in liver cirrhosis. Hepatology 1985, 5(4):643-648.
• [39]Lautt WW, Greenway CV, Legare DJ, Weisman H: Localization of intrahepatic portal vascular resistance. Am J Physiol 1986, 251(3 Pt 1):G375-G381.
• [40]Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F: Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005, 25(6):1079-1090.
• [41]Maass-Moreno R, Rothe CF: Nonlinear resistances in hepatic microcirculation. Am J Physiol 1995, 269(6 Pt 2):H1922-H1930.
• [42]Reynaert H, Urbain D, Geerts A: Regulation of sinusoidal perfusion in portal hypertension. Anat Rec (Hoboken) 2008, 291(6):693-698.
• [43]Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB: Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 1977, 72(4 Pt 1):584-589.
• [44]Perello A, Escorsell A, Bru C, Gilabert R, Moitinho E, Garcia-Pagan JC, Bosch J: Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999, 30(6):1393-1397.
• [45]Pomier-Layrargues G, Kusielewicz D, Willems B, Villeneuve JP, Marleau D, Cote J, Huet PM: Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology 1985, 5(3):415-418.
• [46]Thalheimer U, Leandro G, Samonakis DN, Triantos CK, Patch D, Burroughs AK: Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Dig Liver Dis 2005, 37(8):601-608.
• [47]Henriksen JH, Stage JG, Schlichting P, Winkler K: Intraperitoneal pressure: ascitic fluid and splanchnic vascular pressures, and their role in prevention and formation of ascites. Scand J Clin Lab Invest 1980, 40(6):493-501.
• [48]La Mura V, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, Garcia-Pagan JC, Bosch J: Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology 2010, 51(6):2108-2116.
• [49]Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E: Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011, 60(9):1254-1259.
• [50]Gore RW, Bohlen HG: Microvascular pressures in rat intestinal muscle and mucosal villi. Am J Physiol 1977, 233(6):H685-H693.
• [51]Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J, et al.: Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994, 19(5):1095-1099.
• [52]Sen S, De BK, Biswas PK, Biswas J, Das D, Maity AK: Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension. Indian J Gastroenterol 2002, 21(4):145-148.
• [53]Katsuta Y, Aramaki T, Sekiyama T, Satomura K, Okumura H, Okumura K: Plasma volume contraction in portal hypertension. J Hepatol 1993, 17(Suppl 2):S19-S23.
• [54]Sugano S, Kawafune T, Okajima T, Ishii K, Watanabe M, Takamura N: Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998, 43(4):893-897.
• [55]Cereda JM, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D: Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol 1989, 9(2):246-251.
• [56]Bosch J, Masti R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J: Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984, 4(6):1200-1205.
• [57]Pomier-Layrargues G, Villeneuve JP, Willems B, Huet PM, Marleau D: Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo. Gastroenterology 1987, 93(6):1218-1224.
• [58]Aramaki T, Sekiyama T, Katsuta Y, Kurokawa H, Komeichi H, Tsutsui H, Terada H, Ohsuga M, Satomura K, Okumura H: Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. J Hepatol 1992, 15(1-2):48-53.
• [59]Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D: Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986, 27(10):1204-1209.
• [60]Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, Abraldes JG, De Diego A, Albillos A, Bosch J: Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002, 36(6):1367-1373.
• [61]Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ: Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J Gastroenterol 2003, 38(12):1150-1154.
• [62]De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S: Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003, 98(6):1371-1376.
• [63]Escorsell A, Ferayorni L, Bosch J, Garcia-Pagan JC, Garcia-Tsao G, Grace ND, Rodes J, Groszmann RJ: The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997, 112(6):2012-2016.
• [64]Roulot D, Moreau R, Gaudin C, Bacq Y, Braillon A, Hadengue A, Frohly P, Lebrec D: Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology 1992, 102(4 Pt 1):1309-1318.
• [65]Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D: Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987, 7(1):149-154.
• [66]Albillos A, Banares R, Barrios C, Clemente G, Rossi I, Escartin P, Bosch J: Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology 1992, 102(1):248-254.
• [67]Garcia-Tsao G, Groszmann RJ: Portal hemodynamics during nitroglycerin administration in cirrhotic patients. Hepatology 1987, 7(5):805-809.
• [68]Iwao T, Toyonaga A, Sumino M, Takagi K, Ohkubo K, Inoue R, Tanikawa K: Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis. Hepatology 1991, 13(1):124-128.
• [69]Moreau R, Roulot D, Braillon A, Gaudin C, Hadengue A, Bacq Y, Lebrec D: Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: evidence for an impaired cardiopulmonary baroreflex function. Hepatology 1989, 10(1):93-97.
• [70]Bosch J, Bordas JM, Mastai R, Kravetz D, Navasa M, Chesta J, Pizcueta MP, Garcia-Pagan JC, Rodes J: Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology 1988, 8(4):861-865.
• [71]Groszmann RJ, Kravetz D, Bosch J, Glickman M, Bruix J, Bredfeldt J, Conn HO, Rodes J, Storer EH: Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982, 2(6):757-762.
• [72]Bosch J, Kravetz D, Rodes J: Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981, 80(3):518-525.
• [73]Romero G, Kravetz D, Argonz J, Bildozola M, Suarez A, Terg R: Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients. J Hepatol 2000, 32(3):419-425.
• [74]Ibarra FR, Afione C, Garzon D, Barontini M, Santos JC, Arrizurieta E: Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. Eur J Clin Pharmacol 1992, 43(5):477-482.
• [75]Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH: Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 1995, 10(3):256-260.
• [76]Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC: Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 2004, 99(2):390-394.
• [77]Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-Lopez F, Rodes J: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Investig 1981, 11(3):221-229.
• [78]Vlavianos P, Polson RJ, Settin A, Glover J, Westaby D, Williams R: Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis. Br J Clin Pharmacol 1990, 29(1):19-25.
• [79]Luca A, Feu F, Garcia-Pagan JC, Jimenez W, Arroyo V, Bosch J, Rodes J: Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994, 20(1 Pt 1):30-33.
• [80]Krook H: Estimation of portal venous pressure by occlusive hepatic vein catheterization. Scand J Clin Lab Invest 1953, 5(3):285-292.
• [81]Myers JD, Taylor WJ: Occlusive hepatic venous catheterization in the study of the normal liver, cirrhosis of the liver and noncirrhotic portal hypertension. Circulation 1956, 13(3):368-380.
• [82]Paton A, Reynolds TB, Sherlock S: Assessment of portal venous hypertension by catheterisation of hepatic vein. Lancet 1953, 1(6767):918-921.
• [83]Malbrain ML: Different techniques to measure intra-abdominal pressure (IAP): time for a critical re-appraisal. Intensive Care Med 2004, 30(3):357-371.
• [84]Rector WG Jr: Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986, 6(4):221-226.
• [85]Morali GA, Sniderman KW, Deitel KM, Tobe S, Witt-Sullivan H, Simon M, Heathcote J, Blendis LM: Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992, 16(1-2):249-250.
• [86]Meng HC, Lin HC, Tsai YT, Lee FY, Liao DM, Hsia HC, Lin WJ, Chang TT, Lay CS, Wang SS, et al.: Relationships between the severity of cirrhosis and haemodynamic values in patients with cirrhosis. J Gastroenterol Hepatol 1994, 9(2):148-153.
• [87]Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, Escorsell A, Rodriguez-Laiz JM, Gilabert R, Feu F, et al.: Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998, 114(6):1296-1303.
• [88]Flessner M: Effective lymphatic absorption rate is not a useful or accurate term to use in the physiology of peritoneal dialysis. Perit Dial Int 2004, 24(4):313-316. discussion 316-317
• [89]Krediet RT: The effective lymphatic absorption rate is an accurate and useful concept in the physiology of peritoneal dialysis. Perit Dial Int 2004, 24(4):309-313. discussion 316-307
• [90]Rippe B, Stelin G, Ahlmen J: Lymph flow from the peritoneal cavity in CAPD patients. In International symposium on peritoneal dialysis, 3 rd: 1986 1984; Washington D. C. Edited by Maher JF, Winchester JF. Field, Rich and Associates; 1984:24-30.
• [91]Simonsen O, Venturoli D, Wieslander A, Carlsson O, Rippe B: Mass transfer of calcium across the peritoneum at three different peritoneal dialysis fluid Ca2+ and glucose concentrations. Kidney Int 2003, 64(1):208-215.
• [92]Henriksen JH, Lassen NA, Parving HH, Winkler K: Filtration as the main transport mechanism of protein exchange between plasma and the peritoneal cavity in hepatic cirrhosis. Scand J Clin Lab Invest 1980, 40(6):503-513.
• [93]Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A, Bendtsen F, Ring-Larsen H: Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001, 34(1):53-60.
• [94]Zink J, Greenway CV: Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. Gastroenterology 1977, 73(5):1119-1124.
• [95]Shear L, Ching S, Gabuzda GJ: Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970, 282(25):1391-1396.
• [96]Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG: The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117(3):215-220.
• [97]Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS: Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003, 37(2):393-400.
• [98]Rector WG Jr, Reynolds TB: Propranolol in the treatment of cirrhotic ascites. Arch Intern Med 1984, 144(9):1761-1763.
• [99]Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, et al.: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005, 353(21):2254-2261.
• [100]Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G: Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006, 44(4):844-849.
• [101]Garcia-Tsao G, Bosch J: Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010, 362(9):823-832.
• [102]Tincani E, Cioni G, D'Alimonte P, Cristani A, Turrini F, Romagnoli R, Ventura E: Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Eur J Gastroenterol Hepatol 1995, 7(9):893-897.
• [103]Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J: Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 2010, 53(2):273-282.
• [104]Vlachogiannakos J, Tang AK, Patch D, Burroughs AK: Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001, 49(2):303-308.
• [105]Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Gines P: Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012, 61(1):108-116.
• [106]Trotter J, Pieramici E, Everson GT: Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Dig Dis Sci 2005, 50(7):1356-1360.
• [107]Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30(4):639-645.
• [108]Jahn H, Schon D: Cariovascular effects of loop diuretics. In Diuretics II: Chemistry, parmacology, and clinical applications: 1986; Cascais, Portugal. Edited by Puschett J, Greenberg A. Elsevier; 1986:325-331.
• [109]Schohn DC, Jahn HA, Pelletier BC: Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993, 71(3):40A-45A.
• [110]Rippe B, Levin L: Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000, 57(6):2546-2556.
• [111]Henriksen JH, Parving HH, Christiansen LA, Lassen NA, Ring-Larsen H, Winkler K: The effect of ascitic fluid hydrostatic pressure on albumin extravasation rate in patients with cirrhosis of the liver. Scand J Clin Lab Invest 1981, 41(6):601-609.
• [112]Lieberman FL, Ito S, Reynolds TB: Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969, 48(6):975-981.
• [113]Nitta S, Ohnuki T, Ohkuda K, Nakada T, Staub NC: The corrected protein equation to estimate plasma colloid osmotic pressure and its development on a nomogram. Tohoku J Exp Med 1981, 135(1):43-49.
• [114]Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123(6):1839-1847.
• [115]Rodriguez-Laiz JM, Banares R, Echenagusia A, Casado M, Camunez F, Perez-Roldan F, de Diego A, Cos E, Clemente G: Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 1995, 40(10):2121-2127.
• [116]Campagnoli M, Hansson P, Dolcini L, Caridi G, Dagnino M, Candiano G, Bruschi M, Palmqvist L, Galliano M, Minchiotti L: Analbuminemia in a Swedish male is caused by the Kayseri mutation (c228_229delAT). Clinica Chimica Acta 2008, 396(1-2):89-92.
• [117]Russi E, Weigand K: Analbuminemia. Klin Wochenschr 1983, 61(11):541-545.
• [118]Dumont AE: Thoracic-duct-to-esophagus shunt. Transplantation 1987, 43(2):320.
• [119]Dumont AE, Mulholland JH: Flow rate and composition of thoracic-duct lymph in patients with cirrhosis. N Engl J Med 1960, 263:471-474.
• [120]Zotti EF: Prevention and treatment of experimental ascites due to stenosis of the inferior vena cava in dogs. (A new technic of anastomosis between the thoracic duct and the venous system). Acta Chir Ital 1966, 22(6):679-692.
• [121]Dumont AE, Clauss RH, Reed GE, Tice DA: Lymph Drainage in Patients with Congestive Heart Failure. Comparison with Findings in Hepatic Cirrhosis. N Engl J Med 1963, 269:949-952.
• [122]Szabo G, Magyar Z: Effect of increased systemic venous pressure on lymph pressure and flow. Am J Physiol 1967, 212(6):1469-1474.
• [123]Sakai T, Yabuki S, Chang K, Kambayashi T, Nakamura R, Takeyasu N, Taira K, Hirota A, Machii K, Seki K: Effect of increased systemic venous pressure on thoracic duct and peripheral lymph flow in dogs. Lymphology 1985, 18(2):64-67.